Vaccine · 2026
Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Madley-Dowd Paul, Horne Elsie M F, Hulme William J, Palmer Tom M, Walker Venexia, Denholm Rachel, Sterne Jonathan A C
Аннотация
OBJECTIVE: Estimate the effectiveness and comparative effectiveness of booster vaccination with bivalent original/omicron BA.1 mRNA-1273 (Moderna) and original/omicron BA.1 BNT162b2 (Pfizer-BioNTech) against COVID-19 hospitalisation and death in adults aged ≥50 years.
DESIGN: Matched cohort studies emulating target trials.
SETTING: With approval of NHS England, we analysed linked primary care, hospital, and COVID-19 surveillance records available within the OpenSAFELY-TPP research platform.
PARTICIPANTS: For comparison of boosting with no boosting, 3,464,877 adults eligible for booster vaccination during the autumn 2022 UK COVID-19 vaccine rollout, registered with a general practice using the TPP SystmOne clinical information system in England. For the between-vaccine comparison 531,129 boosted pairs.
INTERVENTIONS: Vaccination with bivalent BA.1 mRNA-1273 or BNT162b2.
MAIN OUTCOME MEASURES: COVID-19-related hospital admission or death, non-COVID-19 death, fracture (negative control outcome).
RESULTS: In approximately 2.5-million person-years follow up there were 14,436 COVID-19-related hospital admissions, 1152 COVID-19-related deaths, 32,184 non-COVID-19 deaths, and 52,758 fractures. The 350-day risks/1000 of COVID-19 hospitalisation and COVID-19 death were 3.78 (95% CI 3.65-3.91) and 0.29 (0.26, 0.33) respectively after boosting and 6.81 (6.65-6.98) and 0.61 (0.56, 0.66) without boosting. Over 350 days' follow-up, adjusted hazard ratios were: COVID-19 hospitalisation 0.51 (95% CI 0.50, 0.53); COVID-19 death 0.45 (0.40, 0.51); non-COVID-19 death 0.56 (0.55, 0.58) and fracture 0.89 (0.87, 0.91). Booster effectiveness waned over time, with greatest effectiveness in the first 70 days after vaccination. The 350-day risks of COVID-19 hospitalisation, COVID-19 death and fracture were similar for the two vaccine brands but higher in the bivalent mRNA-1273 group for non-COVID-19 death (risk difference per 1000 0.88 [0.35, 1.40]).
CONCLUSIONS: Rates of COVID-19-related hospitalisation and death were substantially lower after bivalent original/omicron BA.1 mRNA booster vaccine than in people who remained unboosted. Apparent protection against fracture suggests some unmeasured confounding. Outcomes appeared similar for the Moderna and Pfizer-BioNTech vaccines.
DESIGN: Matched cohort studies emulating target trials.
SETTING: With approval of NHS England, we analysed linked primary care, hospital, and COVID-19 surveillance records available within the OpenSAFELY-TPP research platform.
PARTICIPANTS: For comparison of boosting with no boosting, 3,464,877 adults eligible for booster vaccination during the autumn 2022 UK COVID-19 vaccine rollout, registered with a general practice using the TPP SystmOne clinical information system in England. For the between-vaccine comparison 531,129 boosted pairs.
INTERVENTIONS: Vaccination with bivalent BA.1 mRNA-1273 or BNT162b2.
MAIN OUTCOME MEASURES: COVID-19-related hospital admission or death, non-COVID-19 death, fracture (negative control outcome).
RESULTS: In approximately 2.5-million person-years follow up there were 14,436 COVID-19-related hospital admissions, 1152 COVID-19-related deaths, 32,184 non-COVID-19 deaths, and 52,758 fractures. The 350-day risks/1000 of COVID-19 hospitalisation and COVID-19 death were 3.78 (95% CI 3.65-3.91) and 0.29 (0.26, 0.33) respectively after boosting and 6.81 (6.65-6.98) and 0.61 (0.56, 0.66) without boosting. Over 350 days' follow-up, adjusted hazard ratios were: COVID-19 hospitalisation 0.51 (95% CI 0.50, 0.53); COVID-19 death 0.45 (0.40, 0.51); non-COVID-19 death 0.56 (0.55, 0.58) and fracture 0.89 (0.87, 0.91). Booster effectiveness waned over time, with greatest effectiveness in the first 70 days after vaccination. The 350-day risks of COVID-19 hospitalisation, COVID-19 death and fracture were similar for the two vaccine brands but higher in the bivalent mRNA-1273 group for non-COVID-19 death (risk difference per 1000 0.88 [0.35, 1.40]).
CONCLUSIONS: Rates of COVID-19-related hospitalisation and death were substantially lower after bivalent original/omicron BA.1 mRNA booster vaccine than in people who remained unboosted. Apparent protection against fracture suggests some unmeasured confounding. Outcomes appeared similar for the Moderna and Pfizer-BioNTech vaccines.